Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology. Edwards SM, et al. Among authors: barbachano y. Br J Cancer. 2010 Sep 7;103(6):918-24. doi: 10.1038/sj.bjc.6605822. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736950 Free PMC article.
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I. Watkins DJ, et al. Among authors: barbachano y. Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6. Eur J Cancer. 2014. PMID: 24613126 Clinical Trial.
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. Wong R, et al. Among authors: barbachano y. Ann Oncol. 2011 Sep;22(9):2042-2048. doi: 10.1093/annonc/mdq714. Epub 2011 Feb 1. Ann Oncol. 2011. PMID: 21285134 Free article. Clinical Trial.
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I. Dewdney A, et al. Among authors: barbachano y. J Clin Oncol. 2012 May 10;30(14):1620-7. doi: 10.1200/JCO.2011.39.6036. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473163 Clinical Trial.
54 results